ProShare Advisors’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q2 | – | Sell |
-12,946
| Closed | -$119K | – | 2246 |
|
|
2022
Q1 | $119K | Sell |
12,946
-2,971
| -19% | -$22.9K | ﹤0.01% | 2000 |
|
|
2021
Q4 | $112K | Buy |
15,917
+400
| +3% | +$4.18K | ﹤0.01% | 2189 |
|
|
2021
Q3 | $177K | Sell |
15,517
-3,890
| -20% | -$56.9K | ﹤0.01% | 1817 |
|
|
2021
Q2 | $311K | Buy |
19,407
+3,112
| +19% | +$53.4K | ﹤0.01% | 1873 |
|
|
2021
Q1 | $291K | Buy |
16,295
+941
| +6% | +$16.3K | ﹤0.01% | 1825 |
|
|
2020
Q4 | $207K | Buy |
15,354
+3,361
| +28% | +$40.6K | ﹤0.01% | 1832 |
|
|
2020
Q3 | $141K | Sell |
11,993
-419
| -3% | -$5.1K | ﹤0.01% | 1482 |
|
|
2020
Q2 | $183K | Buy |
+12,412
| New | +$184K | ﹤0.01% | 1483 |
|
|
2020
Q1 | – | Sell |
-15,739
| Closed | -$380K | – | 1682 |
|
|
2019
Q4 | $380K | Sell |
15,739
-1,498
| -9% | -$31K | ﹤0.01% | 1212 |
|
|
2019
Q3 | $331K | Buy |
17,237
+66
| +0.4% | +$1.51K | ﹤0.01% | 1175 |
|
|
2019
Q2 | $507K | Sell |
17,171
-2,138
| -11% | -$82.4K | ﹤0.01% | 1009 |
|
|
2019
Q1 | $917K | Buy |
19,309
+154
| +0.8% | +$6.78K | 0.01% | 801 |
|
|
2018
Q4 | $691K | Sell |
19,155
-3,640
| -16% | -$171K | ﹤0.01% | 825 |
|
|
2018
Q3 | $1.4M | Buy |
22,795
+1,513
| +7% | +$97.3K | 0.01% | 689 |
|
|
2018
Q2 | $1.44M | Sell |
21,282
-625
| -3% | -$35K | 0.01% | 705 |
|
|
2018
Q1 | $1.19M | Sell |
21,907
-2,786
| -11% | -$156K | 0.01% | 771 |
|
|
2017
Q4 | $1.48M | Buy |
24,693
+1,970
| +9% | +$119K | 0.01% | 702 |
|
|
2017
Q3 | $1.1M | Buy |
22,723
+2,061
| +10% | +$112K | 0.01% | 709 |
|
|
2017
Q2 | $1.09M | Sell |
20,662
-472
| -2% | -$22K | 0.01% | 712 |
|
|
2017
Q1 | $958K | Sell |
21,134
-5,550
| -21% | -$248K | 0.01% | 763 |
|
|
2016
Q4 | $1.01M | Buy |
26,684
+6,735
| +34% | +$255K | 0.01% | 772 |
|
|
2016
Q3 | $753K | Sell |
19,949
-2,746
| -12% | -$60.6K | 0.01% | 774 |
|
|
2016
Q2 | $399K | Buy |
22,695
+669
| +3% | +$10.8K | 0.01% | 1067 |
|
|
2016
Q1 | $268K | Sell |
22,026
-2,163
| -9% | -$34.2K | ﹤0.01% | 1258 |
|
|
2015
Q4 | $589K | Buy |
24,189
+2,638
| +12% | +$61.6K | 0.01% | 965 |
|
|
2015
Q3 | $382K | Sell |
21,551
-1,352
| -6% | -$24.5K | 0.01% | 1029 |
|
|
2015
Q2 | $404K | Buy |
22,903
+1,496
| +7% | +$27.4K | 0.01% | 1180 |
|
|
2015
Q1 | $671K | Buy |
21,407
+3,268
| +18% | +$94.7K | 0.01% | 1040 |
|
|
2014
Q4 | $529K | Buy |
+18,139
| New | +$460K | 0.01% | 1167 |
|
Other funds holding AERI
DM
JG
RHJA
ProShare Advisors's AERI Position: Q2 2022 in Review
ProShare Advisors sold out of Aerie Pharmaceuticals (AERI) in Q2 2022, closing a stake of 12,946 shares — an estimated $119K sold.
ProShare Advisors first reported a position in AERI in Q4 2014 and held it in 29 quarters. The position peaked at $1.48M in Q4 2017. 137 funds tracked by Wall St. Rank hold AERI as of Q2 2022.
- ProShare Advisors reported no remaining Aerie Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
- ProShare Advisors sold 12,946 Aerie Pharmaceuticals shares in Q2 2022, an estimated $119K.
- ProShare Advisors first reported a position in Aerie Pharmaceuticals in Q4 2014 and held it in 29 quarters.
- ProShare Advisors's Aerie Pharmaceuticals position peaked at $1.48M in Q4 2017.
- 137 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q2 2022.
Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.